Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Debt / NOTE 3.000%10/1
-
Market price (% of par)
-
77.1%
-
Total 13F principal
-
$176,607,744
-
Principal change
-
-$5,177,382
-
Total reported market value
-
$150,781,059
-
Number of holders
-
11
-
Value change
-
+$336,553
-
Number of buys
-
4
-
Number of sells
-
2
Institutional Holders of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 as of Q1 2023
As of 31 Mar 2023,
KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 was held by
11 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$176,607,744
in principal (par value) of the bond.
The largest 10 bondholders included
BRAIDWELL LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, DAVIDSON KEMPNER CAPITAL MANAGEMENT LP, DAVIDSON KEMPNER PARTNERS, LAZARD ASSET MANAGEMENT LLC, Birch Grove Capital LP, CAPSTONE INVESTMENT ADVISORS, LLC, Parkwood LLC, BLB&B Advisors, LLC, and JPMORGAN CHASE & CO.
This page lists
11
institutional bondholders reporting positions
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.